{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:38:07Z","timestamp":1790217487651,"version":"4.1.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":1261,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Chemotherapy-induced dilated cardiomyopathy (CI-DCM) is a well-recognized phenotype of non-ischemic dilated cardiomyopathy (DCM), characterized by poor outcomes. However, a detailed comparison between idiopathic DCM (iDCM) and CI-DCM is still lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>All consecutive DCM patients enrolled in the Trieste Muscle Heart Disease Registry were analysed. CI-DCM and iDCM were defined according to current recommendations. The primary study outcome measure was all-mortality death and secondary outcomes were a) a composite of cardiovascular death\/heart-transplantation\/ventricular-assist-device implantation, and b) major ventricular arrhythmias. The study included 551 patients (499 iDCM and 52 CI-DCM). At enrolment, compared with iDCM, CI-DCM patients were older (51 \u00b1 14 years vs. 58 \u00b1 3 years, respectively, P &amp;lt; 0.001) and had a higher left ventricular ejection fraction (32% \u00b1 9 vs. 35% \u00b1 10, respectively, P = 0.03). Over a median follow-up of 90 months (IQR 54\u2013140 months), CI-DCM patients had a higher incidence of all-cause mortality compared with iDCM (36.5% vs. 8.4% in CI-DCM and iDCM respectively, P &amp;lt; 0.001), while the incidence of major ventricular arrhythmias was higher in the iDCM group compared with CI-DCM (4% vs. 0%, in CI-DCM and iDCM respectively, P = 0.03). The risk of the composite outcome was comparable between the two groups (P = 0.91). At Cox multivariable analysis, the diagnosis of CI-DCM emerged as independently associated to primary outcome (HR 6.42, 95% C.I. 2.52\u201316.31, P &amp;lt; 0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a well-selected DCM cohort, patients with a chemotherapy-induced aetiology had a higher incidence of all-cause mortality compared with iDCM. Conversely, the incidence of life-threatening ventricular arrhythmic events was higher among patients with iDCM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14045","type":"journal-article","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T08:44:07Z","timestamp":1655973847000},"page":"3052-3059","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical Characterization and Natural History of Chemotherapy-Induced Dilated Cardiomyopathy"],"prefix":"10.1093","volume":"9","author":[{"given":"Andrea","family":"Lalario","sequence":"first","affiliation":[{"name":"Department of Cardiology, Azienda Sanitaria Universitaria Integrata Giuliano Isontina (ASUGI), University of Trieste , Trieste ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Del Mestre","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Azienda Sanitaria Universitaria Integrata Giuliano Isontina (ASUGI), University of Trieste , Trieste ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Lo Casto","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Azienda Sanitaria Universitaria Integrata Giuliano Isontina (ASUGI), University of Trieste , Trieste ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Nuzzi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Azienda Sanitaria Universitaria Integrata Giuliano Isontina (ASUGI), University of Trieste , Trieste ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Manca","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Azienda Sanitaria Universitaria Integrata Giuliano Isontina (ASUGI), University of Trieste , Trieste ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel I.","family":"Bromage","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Science, Faculty of Life Science and Medicine, King's College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Barbati","sequence":"additional","affiliation":[{"name":"Biostatistic Unit, University of Trieste , Trieste ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Merlo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Azienda Sanitaria Universitaria Integrata Giuliano Isontina (ASUGI), University of Trieste , Trieste ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Sinagra","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Azienda Sanitaria Universitaria Integrata Giuliano Isontina (ASUGI), University of Trieste , Trieste ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7609-6297","authenticated-orcid":false,"given":"Antonio","family":"Cannat\u00e0","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Azienda Sanitaria Universitaria Integrata Giuliano Isontina (ASUGI), University of Trieste , Trieste ,","place":["Italy"]},{"name":"Department of Cardiovascular Science, Faculty of Life Science and Medicine, King's College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,6,23]]},"reference":[{"key":"2026012114160911700_ehf214045-bib-0001","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/ejhf.1103","article-title":"Evolving concepts in dilated cardiomyopathy","volume":"20","author":"Merlo","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012114160911700_ehf214045-bib-0002","first-page":"171","article-title":"Contemporary etiology and prognosis of dilated non-ischemic cardiomyopathy","volume":"70","author":"Manca","year":"2021","journal-title":"Minerva Cardiol Angiol"},{"key":"2026012114160911700_ehf214045-bib-0003","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/ejhf.1914","article-title":"Contemporary survival trends and aetiological characterization in non-ischaemic dilated cardiomyopathy","volume":"22","author":"Merlo","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114160911700_ehf214045-bib-0004","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1093\/eurheartj\/ehv727","article-title":"Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: A position statement of the ESC working group on myocardial and pericardial diseases","volume":"37","author":"Pinto","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012114160911700_ehf214045-bib-0005","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1093\/eurheartj\/ehz908","article-title":"Dilated cardiomyopathy: So many cardiomyopathies!","volume":"41","author":"Sinagra","year":"2020","journal-title":"Eur Heart J"},{"key":"2026012114160911700_ehf214045-bib-0006","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1001\/jamacardio.2021.5890","article-title":"Association of Titin Variations with Late-Onset Dilated Cardiomyopathy","volume":"7","author":"Cannat\u00e0","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2026012114160911700_ehf214045-bib-0007","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines: The task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012114160911700_ehf214045-bib-0008","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s10741-015-9502-y","article-title":"Chemotherapy-induced cardiomyopathy","volume":"20","author":"Higgins","year":"2015","journal-title":"Heart Fail Rev"},{"key":"2026012114160911700_ehf214045-bib-0009","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1200\/OP.20.00924","article-title":"Monitoring for chemotherapy-related cardiotoxicity in the form of left ventricular systolic dysfunction: A review of current recommendations","volume":"17","author":"Stone","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"2026012114160911700_ehf214045-bib-0010","first-page":"8","article-title":"Chemotherapy induced cardiomyopathy: Pathogenesis, monitoring and management","volume":"1","author":"Shakir","year":"2009","journal-title":"J Clin Med Res"},{"key":"2026012114160911700_ehf214045-bib-0011","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.3390\/jcm9092885","article-title":"Management of Cardiac Toxicity Induced by chemotherapy","volume":"9","author":"Trapani","year":"2020","journal-title":"J Clin Med"},{"key":"2026012114160911700_ehf214045-bib-0012","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.amjcard.2021.08.026","article-title":"Supraventricular tachycardia causing left ventricular dysfunction","volume":"159","author":"Zaffalon","year":"2021","journal-title":"Am J Cardiol"},{"key":"2026012114160911700_ehf214045-bib-0013","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ijcard.2020.08.062","article-title":"Atrial fibrillation in dilated cardiomyopathy: Outcome prediction from an observational registry","volume":"323","author":"Nuzzi","year":"2021","journal-title":"Int J Cardiol"},{"key":"2026012114160911700_ehf214045-bib-0014","article-title":"Prevalence and evolution of right ventricular dysfunction among different genetic backgrounds in dilated cardiomyopathy","volume":"S0828-282X","author":"Manca","year":"2021","journal-title":"Can J Cardiol"},{"key":"2026012114160911700_ehf214045-bib-0015","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehab670","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the heart failure association (HFA) of the ESC","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012114160911700_ehf214045-bib-0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"key":"2026012114160911700_ehf214045-bib-0017","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"29","author":"Nagueh","year":"2016","journal-title":"J Am Soc Echocardiogr"},{"key":"2026012114160911700_ehf214045-bib-0018","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.jacc.2010.11.030","article-title":"Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment","volume":"57","author":"Merlo","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026012114160911700_ehf214045-bib-0019","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"2026012114160911700_ehf214045-bib-0020","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s11897-017-0353-9","article-title":"Prevention of chemotherapy induced cardiomyopathy","volume":"14","author":"Payne","year":"2017","journal-title":"Curr Heart Fail Rep"},{"key":"2026012114160911700_ehf214045-bib-0021","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1056\/NEJM200004133421502","article-title":"Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy","volume":"342","author":"Felker","year":"2000","journal-title":"N Engl J Med"},{"key":"2026012114160911700_ehf214045-bib-0022","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/heartjnl-2018-313234","article-title":"Cardiovascular phenotype and prognosis of patients with heart failure induced by cancer therapy","volume":"105","author":"Nadruz","year":"2019","journal-title":"Heart"},{"key":"2026012114160911700_ehf214045-bib-0023","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1001\/jama.2019.16658","article-title":"Association of Cardiac Resynchronization Therapy with Change in left ventricular ejection fraction in patients with chemotherapy-induced cardiomyopathy","volume":"322","author":"Singh","year":"2019","journal-title":"JAMA"},{"key":"2026012114160911700_ehf214045-bib-0024","first-page":"59","article-title":"Chemotherapy-induced cardiotoxicity","volume":"8","author":"Florescu","year":"2013","journal-title":"M\u00e6dica"},{"key":"2026012114160911700_ehf214045-bib-0025","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1053\/j.seminoncol.2004.08.006","article-title":"Cardiac safety of liposomal anthracyclines","volume":"31","author":"Ewer","year":"2004","journal-title":"Semin Oncol"},{"key":"2026012114160911700_ehf214045-bib-0026","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","article-title":"Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: The OVERCOME trial (preventiOn of left ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of malignant hEmopathies)","volume":"61","author":"Bosch","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026012114160911700_ehf214045-bib-0027","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/MPH.0000000000001118","article-title":"Dexrazoxane significantly reduces anthracycline-induced cardiotoxicity in pediatric solid tumor patients: A systematic review","volume":"40","author":"Liesse","year":"2018","journal-title":"J Pediatr Hematol Oncol"},{"key":"2026012114160911700_ehf214045-bib-0028","doi-asserted-by":"crossref","DOI":"10.1097\/FJC.0000000000001226","article-title":"Cardiotoxicity of chemotherapeutic drugs: An update and future perspectives","author":"Bannister","year":"2022","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026012114160911700_ehf214045-bib-0029","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014708","article-title":"Changes in cardiovascular biomarkers with breast cancer therapy and associations with cardiac dysfunction","volume":"9","author":"Demissei","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026012114160911700_ehf214045-bib-0030","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1002\/ehf2.13462","article-title":"The prognostic value of serial troponin measurements in patients admitted for COVID-19","volume":"8","author":"Nuzzi","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026012114160911700_ehf214045-bib-0031","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.3390\/jcm9082426","article-title":"Sex-specific prognostic implications in dilated cardiomyopathy after left ventricular reverse remodeling","volume":"9","author":"Cannat\u00e0","year":"2020","journal-title":"J Clin Med"},{"key":"2026012114160911700_ehf214045-bib-0032","first-page":"37","article-title":"Sex differences in the long-term prognosis of dilated cardiomyopathy","volume":"36","author":"Cannat\u00e0","year":"2020","journal-title":"Can J Cardiol"},{"key":"2026012114160911700_ehf214045-bib-0033","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","article-title":"Anthracycline-induced cardiomyopathy: Clinical relevance and response to pharmacologic therapy","volume":"55","author":"Cardinale","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026012114160911700_ehf214045-bib-0034","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1186\/s12885-016-2761-8","article-title":"Rationale and design of the multidisciplinary team IntervenTion in cArdio-oNcology study (TITAN)","volume":"16","author":"Pituskin","year":"2016","journal-title":"BMC Cancer"},{"key":"2026012114160911700_ehf214045-bib-0035","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jacc.2020.11.020","article-title":"Strain-guided Management of Potentially Cardiotoxic Cancer Therapy","volume":"77","author":"Thavendiranathan","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026012114160911700_ehf214045-bib-0036","first-page":"24","article-title":"Use of Sacubitril\/valsartan in patients with cardio toxicity and heart failure due to chemotherapy","volume":"6","author":"Gregorietti","year":"2020","journal-title":"Cardiooncology"},{"key":"2026012114160911700_ehf214045-bib-0037","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/HCO.0000000000000614","article-title":"Treatment of chemotherapy-associated cardiomyopathy","volume":"34","author":"Cai","year":"2019","journal-title":"Curr Opin Cardiol"},{"key":"2026012114160911700_ehf214045-bib-0038","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: A position statement and new risk assessment tools from the cardio-oncology study Group of the Heart Failure Association of the European society","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114160911700_ehf214045-bib-0039","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024505","article-title":"Global longitudinal strain is incremental to left ventricular ejection fraction for the prediction of outcome in optimally treated dilated cardiomyopathy patients","volume":"11","author":"Raafs","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2026012114160911700_ehf214045-bib-0040","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.2512","article-title":"Transient versus persistent improved ejection fraction in non-ischaemic dilated cardiomyopathy","author":"Manca","year":"2022","journal-title":"Eur J Heart Fail"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.14045","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.14045","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/9\/5\/3052\/65352395\/eschf_9_5_3052.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/9\/5\/3052\/65352395\/eschf_9_5_3052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:19:14Z","timestamp":1769023154000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/9\/5\/3052\/8323063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,23]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,6,23]]},"published-print":{"date-parts":[[2022,10,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14045","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10]]},"published":{"date-parts":[[2022,6,23]]},"assertion":[{"value":"2022-02-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}